text: Govt eroding value of pharmaceutical sector: Kiran Mazumdar-Shaw - The Times of India
  Indiatimes|The Times of India|The Economic Times|MoreMoreFollowIndia BusinessThe Times of IndiaThe Times of IndiaIndiatimesWeb (by Google)VideoPhotosAdvanced Search »HomeCityIndiaWorldBusinessTechSportsEntertainmentLife & StyleWomenSpiritualityNRIPhotosVideosNavy helicopter makes 'hard' landing in MumbaiFour workers killed at construction site in ...Suvarna Soudha in Belgaum to become a touris...Man leaps off Bandra-Worli sea link but save...Family of four burnt alive in Chennai2 new arterial roads to decongest DelhiBangalore beware: Kochi hailed as 'alternati...Jagan assets case: Trial court begins framin...Youth found hanging in CPM officeFOLLOW TOIBusinessIndia BusinessInternational BusinessMarketsCEO toonsPersonal FinanceMF SimplifiedVideosBudget 2014You are here: Home » Business » India BusinessBreaking News:RELATED ARTICLESRupee gains 9 paise against dollar in e...Rupee plunges 25 paise against dollar i...Rupee rebounds from one-month lows, up ...Get set to pay to enter Cubbon ParkPrithviraj to speak in Trivandrum slangJammu & Kashmir floods: Who's doing wha...Jayalalithaa assets case: Verdict on Se...YOUR FRIENDS' ACTIVITY1of1SPOTLIGHTNewsmakersPeng Liyuan to meet women ministers in Modi govtLiyuan, Xi's wife and a popular singer and Chinese folklore artist, will interact with students of a school in New Delhi and teach them calligraphy.Vishal Sikka likely to outline Infosys' SMAC plan with Q2 resultsLIC to make Ulip comeback amid surge in equities : SK Roy, ChairmanDestination MarsMangalyaan enters the last leg of its journey to MarsThis mission is simply to test the organisation's (ISRO) ability to take something all the way up to Mars, keep it in good health during the journey.Water-holding meteorite suggests that Mars was once habitableNASA spacecraft MAVEN to begin orbiting Mars within daysApple iOS UpdatesApple iOS 8: Why the software is worth installingWith Apple's the new iOS 8 software for iPhones and iPads, other Apple devices start to act like one. Apps on those devices start to unite, too.Bug delays Apple's HealthKit availability on iOS 8Devices, apps act like one under Apple's new software iOS 8100 Indian BillionairesIndia home to 100 billionaires; 6th in the top 10Mumbai, with 28 billionaires is among the top 20 'billionaire cities' globally, which was topped by New York, which is home to 103 billionaires.Kher discusses totalisation pact with US Trade Representative WendyVodafone CEO Vittorio Colao poised to visit India next weekAlibaba's India ForayChina's Alibaba in funding talks with SnapdealAlibaba has been in talks with Snapdeal as it looks to enter India's booming online retail industry, according to two people aware of the development.Alibaba looks to unlock new markets with initial public offeringAlibaba Group Holding Ltd set to price IPO shares amid investor frenzyShah's Nod to Shiv Sena?Amit Shah gives green signal to BJP-Shiv Sena tie-upThe alliance between BJP and Shiv Sena for the assembly elections in Maharashtra will be formally announced in the next 24 to 36 hours, BJP has said.Inexperienced leadership may play spoilsport in Shiv Sena's poll partyAmid strained ties with Sena, Gadkari meets Maharashtra BJP leadersXi's India VisitXi Jinping's visit aims at better trade, investmentBy far, it has only been handshakes, smiles, sight-seeing and a detailed dinner, except for a brief 15 minutes of business between PM Modi and Xi.PM Modi raises issue of incursions with visiting Chinese Prez Xi JinpingXi Jinping's India visit: India to keep a tab on China's defence movesMaking MovesUIDAI to weed out 10-12% wrongful beneficiariesThe government has begun a crackdown on wrongful beneficiaries of its social sector schemes, a move aimed at curbing misappropriation of funds.Modi-led govt plans to penalise CSR defaulters under Companies ActIndia's black money proposals presented at G-20 not feasible: JoePolitical RoundaboutBJP wants Modi to campaign, PM Modi has no timeHow can a super-busy, hands-on PM with a crucial foreign visit lined up find time to campaign extensively for the party, ask senior government officials.US to press India on trade row during PM Modi's Washington visitPM Narendra Modi wanes a little at home and waxes abroadTrending in StartupsGoogle, Microsoft, IBM luring startups with goodiesMicrosoft is offering startups $60,000 in Azure cloud credits along with its Microsoft Azure for BizSpark Plus Offer for software startups in India.Hinduja Global Solutions BPO to set up VC arm to tap into startup poolIndian startups will see more late-stage growth in capital: AccelSmartphone TalksLava, Intex likely to launch Android One devicesLava and Intex, among a new set of Indian handset makers on the Google's Android One programme, are likely to bring handsets next year by early 2015.Direct interface with brokers on decline, trading via smartphones on riseSmartphone users are spending more time on apps: StudyMarket VoicesModi government has renewed optimism: Mark MobiusWith the Modi-led NDA government ensuring renewed optimism, Mark Mobius of Franklin Templeton Investments says that he is 'very bullish on India.'Chris Wood up stakes on Indian markets; top stocks to bet onIndia well insulated from Fed rate hike; Sensex likely to hit 34000AllTOIMy ProfileSign into earn your BadgesModeratorFind and flag inappropriate comments on Timesofindia.com by marking them offensive. Earn the Moderator badge after your action is verified by the site editorModeratorWordsmithHave an opinion? Express it and get the Wordsmith badge for posting relevant comments on articles and photos.WordsmithFrequent FlyerMake Timesofindia.com your news hotspot. Visit the site regularly earn this badge.Frequent FlyerInfluencerYour opinion matters! Get the influencer badge when other people Recommend or Agree with your comments on Timesofindia.com.InfluencerNews KingRead articles, watch exclusive videos or browse through our photo gallery to become a News King on Timesofindia.comNews KingInboxerTop Headlines in your inbox! Subscribe to the TimesofIndia.com. newsletters and become an Inboxer.InboxerMemberMembers are registered users on Timesofindia.com. Only they are qualified to earn badges and points for their activities. So register and get a badge right away!MemberNetworkerGrow your network; get people to follow you to earn the Networker badge on Timesofindia.com.NetworkerSharekhaanShare and recommend the articles, photos and videos you like on Timesofindia.com; earn the Sharekhaan badge!SharekhaanWell ConnectedYou can earn the Well Connected badge by linking your Facebook and Twitter accounts to your Times profile. Remember to add both your ids to get the badge!Well ConnectedMovie BuffWatch a movie and become a critic! Review and rate a movie on TimesofIndia.com to earn a Movie Buff Badge!Movie BuffKnow more about Times PointsRELATED KEYWORDS: Rupee|pharmaceutical industry|Kiran Mazumdar-Shaw|BioconGovt eroding value of pharmaceutical sector: Kiran Mazumdar-ShawEmail this articlePrint this articleShare on RedittGoogle BookmarksNewsvineLive BookmarksTechnoratiYahoo BookmarksBlogmarksDel.icio.usApnaCircleTweetThe author has posted comments on this articleAnshul Dhamija, TNN | Jul 27, 2013, 10.17AM ISTBANGALORE: Announcing Biocon's Q1 results, company chairperson and managing director Kiran Mazumdar-Shaw spoke to TOI on the company's advancements in research and the future of its subsidiary companies. She also spoke of the regulatory uncertainty prevailing in the pharmaceutical sector. Excerpts: Q) Earlier this year you received approvals for your second novel biologic Alzumab (anti-CD6 molecule). When will it be launched and what's the addressable market for the drug in India? We will be launching Alzumab in August. Right now there are about 5 million psoriatic patients in India, but a very small percentage of them actually use biologics (a medicinal preparation created by a biological process). So obviously it's about market creation in India and about converting a lot of people from non-biologics to biologics. Hence, the market potential is huge, but the really big numbers would only kick-in from next fiscal. Q) Are you exploring global licensing partnerships for the anti-CD6 molecule? We are in discussions to partner with global companies for our anti-CD6 molecule asset. Hopefully, we will be able to conclude something this fiscal, if not then next fiscal. Q) Do you expect to continue your Q1 revenue and profit run rate over the next three quarters? That's the hope. Our Q1 performance is a reflection of the positive outcomes of the SBUs (strategic business units) based organization structure introduced last year, which has brought in greater efficiencies into the system and enabled robust growth across all businesses. We are confident that this will propel us further on to our goal of achieving US $1 billion in revenues by 2018. Q) Biocon's board has given an in-principle approval for the merger of Clinigene with Syngene. Is this part of your planned IPO for Syngene in 2015? Well it is in preparation for the IPO process. Syngene offers end-to-end solutions, which right now happens between the two entities. So from an operational efficiency point of view it is better to have the business under one organization. Q) You have been critical of the government's policies towards the pharmaceutical industry. Why so? The last five quarters have shown a decline in growth for the pharmaceutical industry because of regulatory uncertainty. Suddenly the government declares price control on drugs, brings a moratorium on clinical trials, so there has been no stability in the regulatory framework or regulatory system in India. It's ridiculous the way they (government) have gone about eroding value in this sector. Besides, we are eroding the opportunity that the Indian pharmaceutical sector has especially when the rupee is so low. We should be increasing export of our products, but if the government is making it so tough to approve drugs, how can that be achieved? FEATURED ARTICLESInsurance funds pile up for want of bank a/cChinese billionaires list touches 300: ReportTata companies brought on one platformPost another commentShare your views - post your comment belowWe encourage you to login and
  can verify that the email address doesn't belong to someone else.Register/LoginProceed Without RegistrationFull NameLocationEmailSolve6 + 0 =2ProceedThanks!We have sent you a verification email.To verify, just follow the link in the messageResend verification mailEmail sentSort by:Newest|Oldest|Recommended|Most Discussed|Agree|DisagreeTHE TIMES OF INDIAPowered by INDIATIMESAbout usAdvertise with usTerms of Use and Grievance Redressal PolicyPrivacy policyFeedbackRSSNewsletterTOI MobileePaperSitemapArchivesOther Times Group news sitesThe Economic Timesइकनॉमिक टाइम्स | ઈકોનોમિક ટાઈમ્સMumbai Mirror | Times NowIndiatimes | नवभारत टाइम्समहाराष्ट्र टाइम्स | ವಿಜಯ ಕರ್ನಾಟಕGo GreenLiving and entertainmentTimescity | iDiva | Bollywood | ZoomHealthmeup | Luxpresso | TechnoholikGuylifeInterest Networkitimes | EmailHot on the WebHotklixServicesBook print ads | Online shopping | Business solutions | Book domains | Web hostingBusiness email | Free SMS | Free email | Website design | CRM | Tenders | RemitCheap air tickets | Matrimonial | Ringtones | Astrology | Jobs | Property | Buy carBikes in India | Deals | Free ClassifiedsCopyright © 2012 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication ServiceFind this comment offensive?Choose your reason below and click on the Submit button. This will alert our moderators to take actionNameReason for reporting:Foul languageDefamatoryInciting hatred against a certain communityOut of context/SpamOthersYour Reason has been Submitted to the admin.companies.She also spoke of the regulatory uncertainty prevailing.';